Radiotherapy as a surgical alternative in ductal carcinoma in situ (DCIS): long-term survival benefits and predictors of invasive progression risk

放射疗法作为导管原位癌(DCIS)手术的替代方案:长期生存获益和侵袭性进展风险的预测因素

阅读:1

Abstract

BACKGROUND: Currently, the incidence of ductal carcinoma in situ (DCIS) is gradually increasing. Considering its overall favorable prognosis, some studies have explored exempting patients from surgery for potentially low-risk patients. This retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database investigates whether omitting surgery and administering only local radiotherapy (RT) affects the prognosis of patients. METHODS: A total of 2,363 patients with DCIS who did not receive surgery were identified from the SEER database. Propensity score matching (PSM) and Kaplan-Meier method were applied to analyze the impact of RT alone. Cox regression analyses and competitive risk models were used to examine factors related to the progression of DCIS to invasive cancer. RESULTS: After PSM, there were 194 patients in each of the RT and non-RT groups. Overall survival (OS) at 10 years (93.17% RT vs. 78.09% non-RT, P=0.001), breast cancer-specific survival (BCSS) at 10 years (99.45% RT vs. 90.50% non-RT, P<0.001), and invasive breast cancer progression (iBCP) at 10 years (4.23% RT vs. 13.35% non-RT, P<0.001) were statistically different between the two groups. Specific characteristics like upper outer quadrant location, certain histological types, and hormone receptor-positive status, were associated with survival benefits from RT alone. CONCLUSIONS: Based on the study of the SEER database, we found that RT alone can effectively improve patient outcomes, with a relatively low 10-year iBCP rate. Factors such as histological type, tumor size, histological grade, and hormone receptor status can influence the survival benefits and risk of RT alone for invasive breast cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。